| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2023 | Gosling SB, Arnold EL, Davies SK, Cross H, Bouybayoune I, Calabrese D, Nallala J, Pinder SE, Fu L, Lips EH, King L, Marks J, Hall A, Grimm LJ, Lynch T, et al. Microcalcification crystallography as a potential marker of DCIS recurrence. Scientific Reports. 13: 9331. PMID 37291276 DOI: 10.1038/s41598-023-33547-8 | 0.327 | |||
| 2022 | Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, Simpson LA, Vennam S, Khan A, Cisneros L, Hardman T, Harmon B, Couch F, Gallagher K, Kilgore M, ... ... Marks JR, et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. PMID 36400020 DOI: 10.1016/j.ccell.2022.10.021 | 0.323 | |||
| 2022 | Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, ... ... Marks JR, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics. 54: 850-860. PMID 35681052 DOI: 10.1038/s41588-022-01082-3 | 0.304 | |||
| 2022 | Risom T, Glass DR, Averbukh I, Liu CC, Baranski A, Kagel A, McCaffrey EF, Greenwald NF, Rivero-Gutiérrez B, Strand SH, Varma S, Kong A, Keren L, Srivastava S, Zhu C, ... ... Marks JR, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 185: 299-310.e18. PMID 35063072 DOI: 10.1016/j.cell.2021.12.023 | 0.315 | |||
| 2021 | Stanton SE, Gad E, Ramos E, Corulli L, Annis J, Childs J, Katayama H, Hanash S, Marks J, Disis ML. Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. Npj Breast Cancer. 7: 50. PMID 33976232 DOI: 10.1038/s41523-021-00257-1 | 0.351 | |||
| 2020 | Ryser MD, Mallo D, Hall A, Hardman T, King LM, Tatishchev S, Sorribes IC, Maley CC, Marks JR, Hwang ES, Shibata D. Minimal barriers to invasion during human colorectal tumor growth. Nature Communications. 11: 1280. PMID 32152322 DOI: 10.1038/S41467-020-14908-7 | 0.349 | |||
| 2020 | Lin CC, Mabe NW, Lin YT, Yang WH, Tang X, Hong L, Sun T, Force J, Marks JR, Yao TP, Alvarez JV, Chi JT. RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. Cell Death and Differentiation. PMID 31988496 DOI: 10.1038/S41418-020-0499-Y | 0.424 | |||
| 2020 | Adams D, Lin SH, Pass HI, Chumsri S, Lapidus RG, Edelman M, Bergan RC, Tsai S, Aft R, Pillai S, Watson M, Kim AK, Chikamatsu K, Hayashi M, Loeb DM, ... ... Marks JR, et al. Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors. Journal of Clinical Oncology. 38: 3535-3535. DOI: 10.1200/Jco.2020.38.15_Suppl.3535 | 0.338 | |||
| 2020 | Force JM, Taylor ML, Drusbosky L, Yen J, Marcom PK, Anders CK, Marks JR. Identification of pathogenic ROS1 alterations in cell-free DNA (cfDNA) from patients with breast cancer. Journal of Clinical Oncology. 38: 1031-1031. DOI: 10.1200/Jco.2020.38.15_Suppl.1031 | 0.476 | |||
| 2020 | Force J, Sokol ES, Taylor ML, Huang D, Marcom PK, Davare M, Marks J. Abstract P3-06-09: Incidence of ROS1 genomic alterations in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-06-09 | 0.421 | |||
| 2020 | Angel PM, Saunders J, Jensen-Smith H, Bruner E, Ford ME, Berkhiser S, Boxall B, Bethard J, Ball LE, Yeh ES, Hollingsworth MA, Mehta AS, Marks JR, Nakshatri H, Drake RR. Abstract P2-10-18: Deciphering racial disparities in breast cancer collagen reorganization by targeted extracellular matrix proteomics Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P2-10-18 | 0.39 | |||
| 2020 | Rosenberg SM, Hendrix LH, Schreiber KL, Thompson AM, Bedrosian I, Hughes KS, Lynch T, Basila D, Collyar DE, Frank ES, Darai S, Lanahan C, Marks JR, Plichta JK, Hyslop T, et al. Abstract P1-21-07: The Patient-reported Outcomes after Routine Treatment of Atypical Lesions (PORTAL) study: Pain, psychosocial wellbeing, and quality of life among women undergoing guideline concordant care for DCIS vs. active surveillance for in situ and atypical lesions Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-21-07 | 0.307 | |||
| 2020 | Force J, Qin X, Zhang D, Marcom PK, Marks J, Taylor ML, Anders C, Owzar K, Xie J. Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-06-02 | 0.472 | |||
| 2020 | Ryser MD, Sorribes IC, Greenwald M, Hall A, Mallo D, King LM, Hardman T, Simpson L, Maley CC, Marks JR, Shibata D, Hwang ES. Abstract 2683: Ductal carcinoma in situ is a multiclonal disease Cancer Research. 80: 2683-2683. DOI: 10.1158/1538-7445.Am2020-2683 | 0.429 | |||
| 2020 | Fortunato A, Mallo D, King L, Hardman T, Hall A, Marks JR, Hwang SS, Maley CC. Abstract 2502: Genetic and functional heterogeneity of DCIS as predictors of invasive cancer Cancer Research. 80: 2502-2502. DOI: 10.1158/1538-7445.Am2020-2502 | 0.393 | |||
| 2019 | Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, ... ... Marks JR, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports. 29: 889-903.e10. PMID 31644911 DOI: 10.1016/J.Celrep.2019.09.032 | 0.384 | |||
| 2019 | Hou R, Mazurowski MA, Grimm LJ, Marks JR, King LM, Maley CC, Hwang ES, Lo JY. Prediction of Upstaged Ductal Carcinoma in situ Using Forced Labeling and Domain Adaptation. Ieee Transactions On Bio-Medical Engineering. PMID 31502960 DOI: 10.1109/Tbme.2019.2940195 | 0.333 | |||
| 2019 | Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, ... ... Marks JR, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology. PMID 31160797 DOI: 10.1038/S41590-019-0400-7 | 0.427 | |||
| 2019 | Mazurowski MA, Saha A, Harowicz MR, Cain EH, Marks JR, Marcom PK. Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer. Journal of Magnetic Resonance Imaging : Jmri. PMID 30672045 DOI: 10.1002/Jmri.26648 | 0.414 | |||
| 2019 | Fackler M, Cho S, Cope L, Gabrielson E, Wilsbach K, Lynch C, Marks J, Geradts J, Regan M, Viale G, Wolff A, Umbricht C, Sukumar S. Abstract P4-08-09: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-08-09 | 0.417 | |||
| 2019 | Fortunato A, Mallo D, King L, Hardman T, Hall A, Marks J, Hwang S, Maley C. Abstract P3-06-12: Genetic heterogeneity of DCIS is a predictor of invasive cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-06-12 | 0.444 | |||
| 2018 | Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Research and Treatment. PMID 30328048 DOI: 10.1007/S10549-018-4990-9 | 0.348 | |||
| 2018 | Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, et al. LncRNA CamK-A Regulates Ca-Signaling-Mediated Tumor Microenvironment Remodeling. Molecular Cell. PMID 30220561 DOI: 10.1016/J.Molcel.2018.08.014 | 0.361 | |||
| 2018 | Saha A, Harowicz MR, Cain EH, Hall AH, Hwang ES, Marks JR, Marcom PK, Mazurowski MA. Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. Breast Cancer Research and Treatment. PMID 29992418 DOI: 10.1007/S10549-018-4879-7 | 0.436 | |||
| 2018 | Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, ... ... Marks JR, et al. Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer. Cancer Research. PMID 29967256 DOI: 10.1158/0008-5472.Can-17-0385 | 0.479 | |||
| 2018 | Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, Wang Z, Wang Q, Li A, Marks JR, Guo C, Chen Y, Zhou J, Yang L, Lin C, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Letters. PMID 29803789 DOI: 10.1016/J.Canlet.2018.05.033 | 0.388 | |||
| 2018 | Adams DL, Lin SH, Alpaugh RK, Ho T, Marks JR, Martin SS, Tsai S, Chumsri S, Tang C, Cristofanilli M, Bergan R. Abstract 2631: Cancer associated macrophage-like (CAMLs) cells in blood predict progression and survival for all stages of solid tumors Cancer Research. 78: 2631-2631. DOI: 10.1158/1538-7445.Am2018-2631 | 0.381 | |||
| 2017 | Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Marks JR, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553 | 0.425 | |||
| 2017 | Zheng X, Han H, Liu GP, Ma YX, Pan RL, Sang LJ, Li RH, Yang LJ, Marks JR, Wang W, Lin A. LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. The Embo Journal. PMID 28963395 DOI: 10.15252/Embj.201797609 | 0.442 | |||
| 2017 | Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, Wang S, Park PK, Marks JR, Zhou Y, Zhou J, et al. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. Nature Cell Biology. PMID 28218907 DOI: 10.1038/Ncb3473 | 0.356 | |||
| 2017 | Harowicz MR, Saha A, Grimm LJ, Marcom PK, Marks JR, Hwang ES, Mazurowski MA. Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? Journal of Magnetic Resonance Imaging : Jmri. PMID 28181348 DOI: 10.1002/Jmri.25655 | 0.34 | |||
| 2017 | Adams D, Adams DK, Lin SH, Cristofanilli M, Bergan RC, Marks JR, Martin SS, Chumsri S, Ho TH, Lapidus RG, Tsai S, Tang C, Alpaugh RK. Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies. Journal of Clinical Oncology. 35: 11503-11503. DOI: 10.1200/Jco.2017.35.15_Suppl.11503 | 0.354 | |||
| 2017 | Ding Y, Marks J, King L, Hall A, Mardis E, Rodrigo A, Maley C, Hwang E. Abstract P1-06-06: Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-06-06 | 0.442 | |||
| 2017 | Adams DL, Alpaugh RK, Lin SH, Marks JR, Bergan R, Martin SS, Chumsri S, Cristofanilli M, Tang C, Stefansson S. Abstract 778: Identifying, subtyping and classifying tumor associated circulating endothelial cells in patients with solid tumors Cancer Research. 77: 778-778. DOI: 10.1158/1538-7445.Am2017-778 | 0.316 | |||
| 2017 | Adams DL, Alpaugh RK, Ho TH, Lin SH, Marks JR, Bergan R, Martin SS, Chumsri S, Tang C, Cristofanilli M. Abstract 3798: Multiplex phenotyping of circulating cancer associated macrophage-like cells in patients with solid tumors Cancer Research. 77: 3798-3798. DOI: 10.1158/1538-7445.Am2017-3798 | 0.393 | |||
| 2017 | Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Can BI-RADS features on mammography be used as a surrogate for expensive genomic testing in breast cancer patients? Proceedings of Spie. 10136. DOI: 10.1117/12.2255866 | 0.349 | |||
| 2017 | Shi B, Grimm LJ, Mazurowski MA, Marks JR, King LM, Maley CC, Hwang ES, Lo JY. Can upstaging of ductal carcinoma in situ be predicted at biopsy by histologic and mammographic features Proceedings of Spie. 10134. DOI: 10.1117/12.2255847 | 0.349 | |||
| 2016 | Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27197300 DOI: 10.1158/1055-9965.Epi-15-1221 | 0.436 | |||
| 2016 | Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH. Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Molecular Systems Biology. 12: 860. PMID 26969729 DOI: 10.15252/Msb.20156506 | 0.38 | |||
| 2016 | Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. Journal of the National Cancer Institute. 108. PMID 26683405 DOI: 10.1093/Jnci/Djv372 | 0.305 | |||
| 2016 | Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang C, Marks JR. Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer. Journal of Clinical Oncology. 34: e23055-e23055. DOI: 10.1200/Jco.2016.34.15_Suppl.E23055 | 0.43 | |||
| 2016 | King L, Marks J, Hall A, Temko D, Graham T, Mardis E, Maley C, Hwang E. Abstract P6-05-03: Genomic diversity of ductal carcinoma in situ (DCIS) as a driver of invasion and metastasis Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-05-03 | 0.444 | |||
| 2016 | Roy LD, Zhou R, Dillon L, Moore L, Puri R, Marks J, Lyerly H, Mukherjee P. Abstract P4-09-16: A monoclonal antibody with exceptional specificity across major breast cancer subtypes Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-09-16 | 0.471 | |||
| 2016 | Doherty JA, Greene CS, Rudd JE, Tafe LJ, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry P, Bentley R, ... ... Marks JR, et al. Abstract 3407: Gene expression subtypes of high grade serous ovarian cancer in African American women Cancer Research. 76: 3407-3407. DOI: 10.1158/1538-7445.Am2016-3407 | 0.39 | |||
| 2015 | Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, ... ... Marks JR, et al. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Research : Bcr. 17: 128. PMID 26384318 DOI: 10.1186/S13058-015-0630-Z | 0.485 | |||
| 2015 | Siamakpour-Reihani S, Owzar K, Jiang C, Turner T, Deng Y, Bean SM, Horton JK, Berchuck A, Marks JR, Dewhirst MW, Secord AA. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecologic Oncology. PMID 26260910 DOI: 10.1016/J.Ygyno.2015.08.001 | 0.406 | |||
| 2015 | Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 435-41. PMID 25471344 DOI: 10.1158/1055-9965.Epi-14-1178 | 0.439 | |||
| 2015 | Das Roy L, Zhou R, Moore LJ, Dillon LM, Puri R, Lyerly K, Marks JR, Mukherjee P. Early detection of breast cancer using a unique tumor specific antibody. Journal of Clinical Oncology. 33: e22153-e22153. DOI: 10.1200/Jco.2015.33.15_Suppl.E22153 | 0.443 | |||
| 2015 | Anderson KS, Pepe M, Marks J, Engstrom P, Patriotis C, Zangar R, Skates S, Lampe P, LaBaer J, Li CI. Abstract P4-02-05: A blinded multicenter phase II study of a panel of plasma biomarkers for the detection of triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-02-05 | 0.413 | |||
| 2015 | Adams D, Alpaugh K, Cristofanilli M, Martin S, Chumsri S, Bergen RC, Tsai S, Edelman M, Zhu P, Li S, Makarova OV, Amstutz PT, Tang C, Marks JR. Abstract 5165: Cancer associated macrophage-like cells as a blood-based biomarker for the screening of solid tumors Cancer Research. 75: 5165-5165. DOI: 10.1158/1538-7445.Am2015-5165 | 0.375 | |||
| 2015 | Skates SJ, Anderson KS, Liu T, Kulasingam V, Rabideau D, Wu C, Gillette M, Godwin AK, Urban N, Lokshin A, Marks J, Diamandis E, Zhang Z, Srivastava S, Kagan J, et al. Abstract 1570: Early Detection Research Network (EDRN) validation of circulating ovarian cancer biomarkers Cancer Research. 75: 1570-1570. DOI: 10.1158/1538-7445.Am2015-1570 | 0.325 | |||
| 2014 | Tang X, Lin CC, Spasojevic I, Iversen ES, Chi JT, Marks JR. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Research : Bcr. 16: 415. PMID 25091696 DOI: 10.1186/S13058-014-0415-9 | 0.435 | |||
| 2014 | Stevens EV, Whitaker R, Guinet A, Chang C, Grenier C, Marks J, McDonnell DP, Murphy SK, Berchuck A, Gaillard S. Abstract 4570: Role of ERRalpha in ovarian cancer Cancer Research. 74: 4570-4570. DOI: 10.1158/1538-7445.Am2014-4570 | 0.476 | |||
| 2013 | Marks JR. Refining the role of BRCA1 in combating oxidative stress. Breast Cancer Research : Bcr. 15: 320. PMID 24314328 DOI: 10.1186/Bcr3583 | 0.423 | |||
| 2013 | Schildkraut JM, Iversen ES, Akushevich L, Whitaker R, Bentley RC, Berchuck A, Marks JR. Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1709-21. PMID 23917454 DOI: 10.1158/1055-9965.Epi-13-0192 | 0.45 | |||
| 2013 | Jin H, Daly DS, Marks JR, Zangar RC. Oxidatively modified proteins as plasma biomarkers in breast cancer. Cancer Biomarkers : Section a of Disease Markers. 13: 193-200. PMID 23912491 DOI: 10.3233/Cbm-130349 | 0.419 | |||
| 2013 | Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, Marks JR, Berchuck A. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecologic Oncology. 129: 159-64. PMID 23274563 DOI: 10.1016/J.Ygyno.2012.12.030 | 0.382 | |||
| 2013 | Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, Berchuck A, Schildkraut JM. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecologic Oncology. 129: 173-8. PMID 23262379 DOI: 10.1016/J.Ygyno.2012.12.027 | 0.315 | |||
| 2013 | Siamakpour-Reihani S, Owzar K, Jiang C, Turner T, Berchuck A, Marks J, Dewhirst M, Secord AA. Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma. Journal of Clinical Oncology. 31: 5509-5509. DOI: 10.1200/Jco.2013.31.15_Suppl.5509 | 0.376 | |||
| 2012 | Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 9-14. PMID 22193641 DOI: 10.1097/Igc.0B013E318231F140 | 0.437 | |||
| 2012 | Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517-525)) Journal of Clinical Oncology. 30: 678. DOI: 10.1200/Jco.2012.42.0331 | 0.315 | |||
| 2012 | Kung H, Marks JR, Chi JA. Abstract 3210: Glutamine synthetase is a genetic determinant of cell-type specific glutamine independence in breast epithelia Cancer Research. 72: 3210-3210. DOI: 10.1158/1538-7445.Am2012-3210 | 0.425 | |||
| 2012 | Scheri R, Power S, Marks J, Seewaldt V, Marcom K, Hwang S. Abstract P4-13-06: Association of Age, Obesity and Incident Breast Cancer Phenotypes Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-13-06 | 0.384 | |||
| 2012 | Berchuck A, Sfakianos G, Whitaker R, Levine D, Murphy S, Marks J, Iversen E. Frequency of the cancer genome atlas expression subtypes differs between early and advanced stage high grade serous ovarian cancers Gynecologic Oncology. 125: S133. DOI: 10.1016/J.Ygyno.2011.12.325 | 0.388 | |||
| 2012 | Sfakianos G, Iversen E, Lowery W, Whitaker R, Akushevich L, Schildkraut J, Marks J, Berchuck A. Clinical translation of the cancer genome atlas signature for ovarian cancer survival Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.101 | 0.377 | |||
| 2011 | Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. Plos Genetics. 7: e1002229. PMID 21852960 DOI: 10.1371/Journal.Pgen.1002229 | 0.404 | |||
| 2011 | Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Research. 71: 6195-207. PMID 21825015 DOI: 10.1158/0008-5472.Can-11-1630 | 0.465 | |||
| 2011 | Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research : Bcr. 13: R62. PMID 21672245 DOI: 10.1186/Bcr2899 | 0.421 | |||
| 2011 | Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1543-51. PMID 21586622 DOI: 10.1158/1055-9965.Epi-10-1248 | 0.443 | |||
| 2011 | Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochemical Pharmacology. 82: 122-30. PMID 21501600 DOI: 10.1016/J.Bcp.2011.03.031 | 0.425 | |||
| 2011 | Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA. Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor. Molecular Endocrinology (Baltimore, Md.). 25: 867-76. PMID 21393447 DOI: 10.1210/Me.2010-0277 | 0.32 | |||
| 2011 | Havrilesky LJ, Sanders GD, Kulasingam S, Chino JP, Berchuck A, Marks JR, Myers ER. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer. 117: 545-53. PMID 21254049 DOI: 10.1002/Cncr.25624 | 0.358 | |||
| 2011 | Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. Journal of Proteome Research. 10: 85-96. PMID 20977275 DOI: 10.1021/Pr100686B | 0.435 | |||
| 2011 | Liggett TE, Melnikov AA, Marks JR, Levenson VV. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. International Journal of Cancer. Journal International Du Cancer. 128: 492-9. PMID 20473856 DOI: 10.1002/Ijc.25363 | 0.307 | |||
| 2011 | Jin H, Daly DS, Tan R, White AM, Marks JR, Zangar RC. Abstract 3182: PTM ELISA microarray for breast cancer biomarker discovery Cancer Research. 71: 3182-3182. DOI: 10.1158/1538-7445.Am2011-3182 | 0.462 | |||
| 2011 | Lowery W, Schildkraut J, Akushevich L, Bentley R, Huntsman D, Marks J, Berchuck A. Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.054 | 0.365 | |||
| 2010 | Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, Murphy SK, Iversen E, Marks JR, Berchuck A. Expression signatures of TP53 mutations in serous ovarian cancers. Bmc Cancer. 10: 237. PMID 20504346 DOI: 10.1186/1471-2407-10-237 | 0.394 | |||
| 2010 | Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. Plos One. 5: e10061. PMID 20386703 DOI: 10.1371/Journal.Pone.0010061 | 0.392 | |||
| 2010 | Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2159-66. PMID 20368574 DOI: 10.1200/Jco.2008.19.2484 | 0.359 | |||
| 2010 | Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2198-206. PMID 20368555 DOI: 10.1200/Jco.2009.26.7245 | 0.457 | |||
| 2010 | Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment. 124: 441-51. PMID 20309627 DOI: 10.1007/S10549-010-0842-Y | 0.392 | |||
| 2010 | Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1466-77. PMID 20179231 DOI: 10.1158/1078-0432.Ccr-09-2549 | 0.319 | |||
| 2010 | Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, ... ... Marks JR, et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 600-4. PMID 20142253 DOI: 10.1158/1055-9965.Epi-09-0861 | 0.365 | |||
| 2010 | Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecologic Oncology. 116: 556-62. PMID 20006900 DOI: 10.1016/J.Ygyno.2009.11.020 | 0.335 | |||
| 2010 | Marcom PK, Barry W, Datto MB, Geradts J, Olson JA, Marks J, Lyman GH, Potti A, Ginsburg GS, Nevins JR. A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. Journal of Clinical Oncology. 28: TPS102-TPS102. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps102 | 0.454 | |||
| 2009 | Westmoreland TJ, Wickramasekara SM, Guo AY, Selim AL, Winsor TS, Greenleaf AL, Blackwell KL, Olson JA, Marks JR, Bennett CB. Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. Plos One. 4: e5830. PMID 19503795 DOI: 10.1371/Journal.Pone.0005830 | 0.766 | |||
| 2009 | Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY. Do serum biomarkers really measure breast cancer? Bmc Cancer. 9: 164. PMID 19476629 DOI: 10.1186/1471-2407-9-164 | 0.395 | |||
| 2009 | Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Role of eotaxin-1 signaling in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2647-56. PMID 19351767 DOI: 10.1158/1078-0432.Ccr-08-2024 | 0.422 | |||
| 2009 | Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2448-55. PMID 19318476 DOI: 10.1158/1078-0432.Ccr-08-2430 | 0.768 | |||
| 2009 | Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 69: 2349-57. PMID 19276375 DOI: 10.1158/0008-5472.Can-08-2902 | 0.353 | |||
| 2009 | Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Research and Treatment. 118: 635-43. PMID 19224362 DOI: 10.1007/S10549-008-0301-1 | 0.447 | |||
| 2009 | Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Molecular Cancer Research : McR. 7: 199-209. PMID 19208741 DOI: 10.1158/1541-7786.Mcr-08-0314 | 0.8 | |||
| 2009 | Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 28: 209-18. PMID 18836486 DOI: 10.1038/Onc.2008.374 | 0.342 | |||
| 2009 | Hardee ME, Eapen RJ, Rabbani ZN, Dreher MR, Marks J, Blackwell KL, Dewhirst MW. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. Cancer Chemotherapy and Pharmacology. 63: 219-28. PMID 18365198 DOI: 10.1007/S00280-008-0729-3 | 0.371 | |||
| 2009 | Anderson K, Sibani S, Wong J, Hainsworth E, Mendoza E, Eugene R, Raphael J, Logvinenko T, Ramachandran N, Godwin A, Marks J, Engstrom P, LaBaer J. Using custom protein microarrays to identify autoantibody biomarkers for the early detection of breast cancer. Cancer Research. 69: 2003. DOI: 10.1158/0008-5472.Sabcs-2003 | 0.435 | |||
| 2009 | Danko M, Olson J, Marks J. QS119. A Germline Polymorphism in SIPA1 Does Not Predict Metastatic Potential in Breast Cancer Journal of Surgical Research. 151: 287. DOI: 10.1016/J.Jss.2008.11.415 | 0.427 | |||
| 2009 | Westmoreland T, Huper G, Marks J, Bennett C, Olson J. 51: A New Role for BRCA1 in mRNA Stability Journal of Surgical Research. 151: 194. DOI: 10.1016/J.Jss.2008.11.061 | 0.745 | |||
| 2008 | Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3324-30. PMID 18612148 DOI: 10.1200/Jco.2007.14.2471 | 0.454 | |||
| 2008 | Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF. ISG15 as a novel tumor biomarker for drug sensitivity. Molecular Cancer Therapeutics. 7: 1430-9. PMID 18566215 DOI: 10.1158/1535-7163.Mct-07-2345 | 0.41 | |||
| 2008 | Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Research : Bcr. 10: R45. PMID 18474099 DOI: 10.1186/Bcr2096 | 0.38 | |||
| 2008 | Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 585-93. PMID 18349276 DOI: 10.1158/1055-9965.Epi-07-0596 | 0.374 | |||
| 2008 | Bennett CB, Westmoreland TJ, Verrier CS, Blanchette CA, Sabin TL, Phatnani HP, Mishina YV, Huper G, Selim AL, Madison ER, Bailey DD, Falae AI, Galli A, Olson JA, Greenleaf AL, ... Marks JR, et al. Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. Plos One. 3: e1448. PMID 18197258 DOI: 10.1371/Journal.Pone.0001448 | 0.786 | |||
| 2008 | Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. Plos One. 3: e1373. PMID 18167534 DOI: 10.1371/Journal.Pone.0001373 | 0.424 | |||
| 2008 | Danko ME, Untch BR, Tebbit CL, Zhai J, Dressman HK, Bentley RC, Baker J, Marks JR, Nevins JR, Olson JA. A clinicogenomic model to predict lymph node metastasis in breast cancer Journal of the American College of Surgeons. 207: S45. DOI: 10.1016/J.Jamcollsurg.2008.06.092 | 0.357 | |||
| 2007 | Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, ... ... Marks JR, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 67: 3027-35. PMID 17409409 DOI: 10.1158/0008-5472.Can-06-3261 | 0.322 | |||
| 2007 | Huper G, Marks JR. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Research. 67: 2990-3001. PMID 17409405 DOI: 10.1158/0008-5472.Can-06-4065 | 0.45 | |||
| 2007 | Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 473-80. PMID 17372242 DOI: 10.1158/1055-9965.Epi-06-0868 | 0.376 | |||
| 2007 | Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 334-41. PMID 17301268 DOI: 10.1158/1055-9965.Epi-06-0681 | 0.377 | |||
| 2007 | Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 517-25. PMID 17290060 DOI: 10.1200/Jco.2006.06.3743 | 0.427 | |||
| 2007 | Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecologic Oncology. 105: 312-20. PMID 17276500 DOI: 10.1016/J.Ygyno.2006.12.017 | 0.409 | |||
| 2007 | Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of Clinical Investigation. 117: 206-17. PMID 17160136 DOI: 10.1172/Jci29293 | 0.469 | |||
| 2007 | Anders CK, Hsu SD, Acharya CR, Zhang Y, Wang Y, Foekens JA, Marcom PK, Marks JR, Nevins J, Potti A, Blackwell KL. Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status Journal of Clinical Oncology. 25: 522-522. DOI: 10.1200/Jco.2007.25.18_Suppl.522 | 0.434 | |||
| 2006 | Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, et al. Genomic signatures to guide the use of chemotherapeutics. Nature Medicine. 12: 1294-300. PMID 17057710 DOI: 10.1038/Nm1491 | 0.309 | |||
| 2006 | Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 16: 1733-45. PMID 17009964 DOI: 10.1111/J.1525-1438.2006.00660.X | 0.454 | |||
| 2006 | Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels International Journal of Gynecological Cancer. 16: 1529-1535. PMID 16884361 DOI: 10.1111/J.1525-1438.2006.00623.X | 0.79 | |||
| 2006 | Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan C, Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Research. 66: 4065-78. PMID 16618726 DOI: 10.1158/0008-5472.Can-05-4083 | 0.444 | |||
| 2006 | Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Molecular Cancer Research : McR. 4: 283-92. PMID 16603642 DOI: 10.1158/1541-7786.Mcr-05-0138 | 0.4 | |||
| 2006 | Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR, Berchuck A. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecologic Oncology. 101: 390-7. PMID 16551475 DOI: 10.1016/J.Ygyno.2006.02.014 | 0.399 | |||
| 2006 | Schafer ZT, Parrish AB, Wright KM, Margolis SS, Marks JR, Deshmukh M, Kornbluth S. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Research. 66: 2210-8. PMID 16489023 DOI: 10.1158/0008-5472.Can-05-3923 | 0.404 | |||
| 2006 | Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, Blackwell K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 819-26. PMID 16467094 DOI: 10.1158/1078-0432.Ccr-05-1447 | 0.49 | |||
| 2006 | Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Research. 34: 555-63. PMID 16432260 DOI: 10.1093/Nar/Gkj468 | 0.367 | |||
| 2006 | Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology (Cambridge, Mass.). 17: 104-7. PMID 16357602 DOI: 10.1097/01.Ede.0000190538.55645.F8 | 0.33 | |||
| 2006 | Brown NM, Stenzel TT, Friedman PN, Henslee J, Huper G, Marks JR. Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Research and Treatment. 97: 41-7. PMID 16319979 DOI: 10.1007/S10549-005-9085-8 | 0.474 | |||
| 2006 | Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439: 353-7. PMID 16273092 DOI: 10.1038/Nature04296 | 0.417 | |||
| 2006 | Tebbit C, Untch B, Dar M, Saito W, Leight G, Marks J, Olson J. Gene expression associated with sestimibi uptake in primary parathyroid adenomas Journal of Surgical Research. 130: 304-305. DOI: 10.1016/J.Jss.2005.11.417 | 0.329 | |||
| 2005 | Sun M, Sun M, Lyons-Weiler J, Lokshin AE, Modugno F, Marks J, Bigbee WL. Serum proteomic profiling distinguishes estrogen receptor (ER) positive and ER negative breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 578. PMID 27946485 DOI: 10.1200/Jco.2005.23.16_Suppl.578 | 0.427 | |||
| 2005 | Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6117-25. PMID 16087946 DOI: 10.1200/Jco.2005.06.075 | 0.366 | |||
| 2005 | Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3686-96. PMID 15897565 DOI: 10.1158/1078-0432.Ccr-04-2398 | 0.402 | |||
| 2005 | Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecologic Oncology. 97: 543-9. PMID 15863158 DOI: 10.1016/J.Ygyno.2005.01.025 | 0.344 | |||
| 2005 | Wang W, Huper G, Guo Y, Murphy SK, Olson JA, Marks JR. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene. 24: 2705-14. PMID 15735726 DOI: 10.1038/Sj.Onc.1208464 | 0.483 | |||
| 2005 | Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR, Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology. 96: 355-61. PMID 15661221 DOI: 10.1016/J.Ygyno.2004.10.012 | 0.4 | |||
| 2005 | Lancaster JM, Bild A, Pittman J, Sayer R, Whitaker RS, Marks J, Mike W, Dressman H, Nevins J, Berchuck A. Gene expression profiles that predict response to platinum and identify patterns of pathway deregulation in advanced ovarian cancer Journal of Clinical Oncology. 23: 5031-5031. DOI: 10.1200/Jco.2005.23.16_Suppl.5031 | 0.387 | |||
| 2005 | Westmoreland TJ, Huper G, Saito W, Marks J, Bennett C, Olson J. The DEAD box helicase DDX6 physically interacts with the tumor suppressor BRCA1 Journal of the American College of Surgeons. 201: S79. DOI: 10.1016/J.Jamcollsurg.2005.06.185 | 0.762 | |||
| 2004 | Wang W, Nahta R, Huper G, Marks JR. TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Molecular Cancer Research : McR. 2: 442-52. PMID 15328371 | 0.675 | |||
| 2004 | Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, Sampson JH, Gromeier M. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4831-8. PMID 15269159 DOI: 10.1158/1078-0432.Ccr-03-0694 | 0.373 | |||
| 2004 | Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. American Journal of Obstetrics and Gynecology. 190: 910-25. PMID 15118612 DOI: 10.1016/J.Ajog.2004.02.005 | 0.414 | |||
| 2004 | Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and Cellular Biology. 24: 3992-4003. PMID 15082792 DOI: 10.1128/Mcb.24.9.3992-4003.2004 | 0.812 | |||
| 2004 | Westmoreland TJ, Marks JR, Olson JA, Thompson EM, Resnick MA, Bennett CB. Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryotic Cell. 3: 430-46. PMID 15075273 DOI: 10.1128/Ec.3.2.430-446.2004 | 0.769 | |||
| 2004 | Tebbit CL, Bentley RC, Olson JA, Marks JR. Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes, Chromosomes & Cancer. 40: 51-4. PMID 15034868 DOI: 10.1002/Gcc.20017 | 0.436 | |||
| 2004 | Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A. Gene expression patterns that characterize advanced stage serous ovarian cancers. Journal of the Society For Gynecologic Investigation. 11: 51-9. PMID 14706684 DOI: 10.1016/J.Jsgi.2003.07.004 | 0.411 | |||
| 2004 | Tebbit CL, Marks JR, Dressman H, Blanchette C, Iverson E, Pittman J, Olson JA. Gene expression signature characterizing cyclin E protein overexpression in primary breast tumors Journal of the American College of Surgeons. 199: 78-79. DOI: 10.1016/J.Jamcollsurg.2004.05.170 | 0.795 | |||
| 2003 | Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domenici J, Bae YK, Monitto CL, Merlos-Suarez A, Chan J, Hulette CM, Richardson A, Morton CC, Marks J, Duyao M, et al. A neural survival factor is a candidate oncogene in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 100: 10931-6. PMID 12953101 DOI: 10.1073/Pnas.1932980100 | 0.456 | |||
| 2003 | Westmoreland TJ, Olson JA, Saito WY, Huper G, Marks JR, Bennett CB. Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast. The Journal of Surgical Research. 113: 62-73. PMID 12943812 DOI: 10.1016/S0022-4804(03)00155-0 | 0.796 | |||
| 2003 | Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A, Peng Y, Pei L, Marks JR, Lowe S, Hoey T, et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 3: 297-302. PMID 12676587 DOI: 10.1016/S1535-6108(03)00054-0 | 0.475 | |||
| 2003 | Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K. Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research : McR. 1: 362-75. PMID 12651909 | 0.353 | |||
| 2003 | Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival Clinical Cancer Research. 9: 762-766. PMID 12576447 | 0.771 | |||
| 2003 | Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer Journal of the Society For Gynecologic Investigation. 10: 381-387. DOI: 10.1016/S1071-55760300141-2 | 0.328 | |||
| 2002 | Spang R, Zuzan H, West M, Nevins J, Blanchette C, Marks JR. Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biology. 2: 369-81. PMID 12542420 | 0.785 | |||
| 2002 | Gilliam LK, Lobenhofer EK, Greer PK, Scearce RM, Cirisano FD, Marks JR, Hale LP. BRCA2 monoclonal antibodies react with differentiating epithelium. Hybridoma and Hybridomics. 21: 261-9. PMID 12193279 DOI: 10.1089/153685902760213877 | 0.74 | |||
| 2002 | Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nature Genetics. 31: 133-4. PMID 12021784 DOI: 10.1038/Ng888 | 0.436 | |||
| 2001 | Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecologic Oncology. 83: 491-500. PMID 11733961 DOI: 10.1006/Gyno.2001.6464 | 0.426 | |||
| 2001 | West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 98: 11462-7. PMID 11562467 DOI: 10.1073/Pnas.201162998 | 0.801 | |||
| 2001 | Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 98: 9796-801. PMID 11481438 DOI: 10.1073/Pnas.171138398 | 0.512 | |||
| 2001 | Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 20: 3348-53. PMID 11423985 DOI: 10.1038/Sj.Onc.1204438 | 0.458 | |||
| 2001 | Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. Journal of the Society For Gynecologic Investigation. 8: 104-13. PMID 11336882 DOI: 10.1177/107155760100800208 | 0.694 | |||
| 2000 | Lobenhofer EK, Marks JR. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. The Journal of Steroid Biochemistry and Molecular Biology. 75: 11-20. PMID 11179904 DOI: 10.1016/S0960-0760(00)00132-1 | 0.675 | |||
| 2000 | Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature. 405: 974-8. PMID 10879542 DOI: 10.1038/35016125 | 0.434 | |||
| 2000 | Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 97: 6049-54. PMID 10811911 DOI: 10.1073/Pnas.100566997 | 0.513 | |||
| 2000 | Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 99-110. PMID 10714766 | 0.668 | |||
| 1999 | Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Managing hereditary ovarian cancer risk. Cancer. 86: 2517-24. PMID 10630177 DOI: 10.1002/(Sici)1097-0142(19991201)86:11+<2517::Aid-Cncr8>3.0.Co;2-B | 0.384 | |||
| 1999 | Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Isolation and initial characterization of the BRCA2 promoter. Oncogene. 18: 6000-12. PMID 10557089 DOI: 10.1038/Sj.Onc.1202990 | 0.37 | |||
| 1999 | Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Dooley W, Amshey SR, Sukumar S. Telomerase activity and prognosis in primary breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3075-81. PMID 10506602 DOI: 10.1200/Jco.1999.17.10.3075 | 0.445 | |||
| 1999 | Lambers AR, Gumbs C, Ali S, Marks JR, Iglehart JD, Berchuck A, Futreal PA. Bcl10 is not a target for frequent mutation in human carcinomas. British Journal of Cancer. 80: 1575-6. PMID 10408401 DOI: 10.1038/Sj.Bjc.6690564 | 0.373 | |||
| 1999 | Umbricht CB, Sherman ME, Dome J, Carey LA, Marks J, Kim N, Sukumar S. Telomerase activity in ductal carcinoma in situ and invasive breast cancer Oncogene. 18: 3407-3414. PMID 10362362 DOI: 10.1038/Sj.Onc.1202714 | 0.427 | |||
| 1999 | Dong Q, Johnson SP, Colvin OM, Bullock N, Kilborn C, Runyon G, Sullivan DM, Easton J, Bigner DD, Nahta R, Marks J, Modrich P, Friedman HS. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemotherapy and Pharmacology. 43: 73-9. PMID 9923544 DOI: 10.1007/S002800050865 | 0.604 | |||
| 1998 | Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cellular Immunology. 190: 141-55. PMID 9878115 DOI: 10.1006/Cimm.1998.1390 | 0.363 | |||
| 1998 | Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers Journal of the Society For Gynecologic Investigation. 5: 281-285. PMID 9773405 DOI: 10.1016/S1071-5576(98)00018-5 | 0.516 | |||
| 1998 | Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP. Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2 Clinical Obstetrics and Gynecology. 41: 157-166. PMID 9504233 DOI: 10.1097/00003081-199803000-00022 | 0.411 | |||
| 1998 | Burke HB, Hoang A, Iglehart JD, Marks JR. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer. 82: 874-7. PMID 9486576 DOI: 10.1002/(Sici)1097-0142(19980301)82:5<874::Aid-Cncr11>3.0.Co;2-Y | 0.304 | |||
| 1998 | Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. British Journal of Cancer. 77: 51-6. PMID 9459145 DOI: 10.1038/Bjc.1998.8 | 0.38 | |||
| 1997 | Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell FE, Marks JR, Winchester DP, Bostwick DG. Artificial neural networks improve the accuracy of cancer survival prediction Cancer. 79: 857-862. PMID 9024725 DOI: 10.1002/(Sici)1097-0142(19970215)79:4<857::Aid-Cncr24>3.0.Co;2-Y | 0.334 | |||
| 1997 | Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. BRCA1 expression is not directly responsive to estrogen Oncogene. 14: 115-121. PMID 9010238 DOI: 10.1038/Sj.Onc.1200808 | 0.457 | |||
| 1996 | Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Research. 24: 4558-64. PMID 8948649 DOI: 10.1093/Nar/24.22.4558 | 0.381 | |||
| 1996 | Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer Molecular Carcinogenesis. 17: 160-162. PMID 8944076 DOI: 10.1002/(Sici)1098-2744(199611)17:3<160::Aid-Mc8>3.0.Co;2-J | 0.374 | |||
| 1996 | Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A. p53 overexpression in advanced-stage endometrial adenocarcinoma American Journal of Obstetrics and Gynecology. 175: 1246-1252. PMID 8942496 DOI: 10.1016/S0002-9378(96)70036-4 | 0.316 | |||
| 1996 | Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Role of BRCA1 mutation screening in the management of familial ovarian cancer American Journal of Obstetrics and Gynecology. 175: 738-746. PMID 8828444 DOI: 10.1053/Ob.1996.V175.A74288 | 0.419 | |||
| 1996 | Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, ... ... Marks JR, et al. BRCA2 mutations in primary breast and ovarian cancers Nature Genetics. 13: 238-240. PMID 8640235 DOI: 10.1038/Ng0696-238 | 0.465 | |||
| 1995 | Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proceedings of the National Academy of Sciences of the United States of America. 92: 8338-42. PMID 7667291 DOI: 10.1073/Pnas.92.18.8338 | 0.444 | |||
| 1995 | Iglehart JD, Kerns BJ, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer Breast Cancer Research and Treatment. 34: 253-263. PMID 7579490 DOI: 10.1007/Bf00689717 | 0.46 | |||
| 1995 | Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, Iglehart JD, Deininger PL, McDonnell DP. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. The Journal of Biological Chemistry. 270: 22777-82. PMID 7559405 DOI: 10.1074/Jbc.270.39.22777 | 0.316 | |||
| 1995 | Layfield LJ, Kerns BM, Conlon DH, Iglehart JD, Marks JR, Dodge RK. Determination of Proliferation Index By MIB-1 Immunostaining in Early Stage Breast Cancer Using Quantitative Image Analysis The Breast Journal. 1: 362-371. DOI: 10.1111/J.1524-4741.1995.Tb00263.X | 0.411 | |||
| 1994 | Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers American Journal of Obstetrics and Gynecology. 170: 246-252. PMID 8296829 DOI: 10.1016/S0002-9378(94)70414-7 | 0.429 | |||
| 1994 | Pykett MJ, Murphy ME, Harnish PR, Muenke M, Marks J, George DL. Loss of chromosome 8p sequences in human breast carcinoma cell lines. Cancer Genetics and Cytogenetics. 76: 23-8. PMID 8076345 DOI: 10.1016/0165-4608(94)90064-7 | 0.4 | |||
| 1994 | Futreal PA, Cochran C, Rosenthal J, Miki Y, Swenson J, Hobbs M, Bennett LM, Haugen-strano A, Marks J, Barrett JC, Tavtlglan SV, Shattuck-eldens D, Kamb A, Skolnick M, Wiseman RW. Isolation of a diverged homeobox gene, M0X1, from the BRCA1 region on 17q21 by solution hybrid capture Human Molecular Genetics. 3: 1359-1364. PMID 7987315 DOI: 10.1093/Hmg/3.8.1359 | 0.402 | |||
| 1994 | Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, ... ... Marks J, et al. BRCA1 mutations in primary breast and ovarian carcinomas Science. 266: 120-122. PMID 7939630 DOI: 10.1126/Science.7939630 | 0.452 | |||
| 1994 | Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJM, Iglehart JD. Overexpression of p53 and HER-2/ neu proteins as prognostic markers in early stage breast cancer Annals of Surgery. 219: 332-341. PMID 7909221 DOI: 10.1097/00000658-199404000-00002 | 0.446 | |||
| 1994 | Kamb A, Futreal PA, Rosenthal J, Cochran C, Harshman KD, Liu Q, Phelps RS, Tavtigian SV, Tran T, Hussey C, Bell R, Miki Y, Swensen J, Hobbs MR, Marks J, et al. Localization of the VHR Phosphatase Gene and Its Analysis as a Candidate for BRCA1 Genomics. 23: 163-167. PMID 7829067 DOI: 10.1006/Geno.1994.1473 | 0.487 | |||
| 1994 | Lightner VA, Marks JR, Mccachren SS. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue Experimental Cell Research. 210: 177-184. PMID 7507849 DOI: 10.1006/Excr.1994.1027 | 0.37 | |||
| 1994 | Berchuck A, Kohler M, Marks J, Wiseman R, Boyd J, Bast R. The p53 tumor suppressor gene frequently is altered in gynecologic cancers International Journal of Gynecology & Obstetrics. 47: 201-201. DOI: 10.1016/0020-7292(94)90398-0 | 0.432 | |||
| 1993 | Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. American Journal of Obstetrics and Gynecology. 169: 690-4. PMID 8372881 DOI: 10.1016/0002-9378(93)90644-X | 0.342 | |||
| 1993 | Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer Journal of the National Cancer Institute. 85: 1513-1519. PMID 8360934 DOI: 10.1093/Jnci/85.18.1513 | 0.412 | |||
| 1993 | Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive Production of Macrophage Colony-Stimulating Factor and Interleukin-6 by Human Ovarian Surface Epithelial Cells Experimental Cell Research. 207: 332-339. PMID 8344385 DOI: 10.1006/Excr.1993.1200 | 0.331 | |||
| 1993 | Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. American Journal of Obstetrics and Gynecology. 167: 1877-82. PMID 1361720 DOI: 10.1016/0002-9378(92)91790-H | 0.357 | |||
| 1993 | Boente M, Berchuck A, Rodriguez G, Davidoff A, Whitaker R, Xu F, Marks J, Clarke-Pearson D, Bast R. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells International Journal of Gynecology & Obstetrics. 42: 226-227. DOI: 10.1016/0020-7292(93)90683-N | 0.314 | |||
| 1992 | Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 40: 1047-51. PMID 1607637 DOI: 10.1177/40.7.1607637 | 0.418 | |||
| 1992 | Huper G, Marks JR, Wiener JR, Iglehart JD. Relative promoter activity in human mammary epithellal cells assayed by transient expression In Vitro Cellular and Developmental Biology - Animal. 28: 730-734. PMID 1483964 DOI: 10.1007/Bf02631061 | 0.359 | |||
| 1992 | Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, Humphrey P, Berchuck A, Ponder BAJ, Bast RC. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and x-chromosome inactivation Journal of the National Cancer Institute. 84: 1793-1798. PMID 1433368 DOI: 10.1093/Jnci/84.23.1793 | 0.43 | |||
| 1992 | Davidoff AM, Dirk Iglehart J, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers Proceedings of the National Academy of Sciences of the United States of America. 89: 3439-3442. PMID 1373500 DOI: 10.1073/Pnas.89.8.3439 | 0.387 | |||
| 1991 | Davidoff AM, Humphrey PA, Dirk Iglehart J, Marks JR. Genetic basis for p53 overexpression in human breast cancer Proceedings of the National Academy of Sciences of the United States of America. 88: 5006-5010. PMID 2052583 DOI: 10.1073/Pnas.88.11.5006 | 0.415 | |||
| 1991 | Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. p53 alterations in all stages of breast cancer. Journal of Surgical Oncology. 48: 260-7. PMID 1745051 DOI: 10.1002/Jso.2930480409 | 0.48 | |||
| 1991 | Pence JC, Kizilbash AM, Kerns BJ, Marks JR, Iglehart JD. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. Journal of Surgical Oncology. 48: 11-20. PMID 1716331 DOI: 10.1002/Jso.2930480104 | 0.426 | |||
| 1989 | Marks JR, Lin J, Hinds P, Miller D, Levine AJ. Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen Journal of Virology. 63: 790-797. PMID 2642978 DOI: 10.1128/Jvi.63.2.790-797.1989 | 0.331 | |||
| 1987 | van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice Journal of Virology. 61: 2029-2032. PMID 3033329 DOI: 10.1128/Jvi.61.6.2029-2032.1987 | 0.31 | |||
| Show low-probability matches. | |||||